GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oculis Holding AG (FRA:CR5) » Definitions » Cash Flow from Others

Oculis Holding AG (FRA:CR5) Cash Flow from Others : €8.38 Mil (TTM As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Oculis Holding AG Cash Flow from Others?

Oculis Holding AG's cash flow from others for the three months ended in Mar. 2024 was €2.00 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Mar. 2024 was €8.38 Mil.


Oculis Holding AG Cash Flow from Others Historical Data

The historical data trend for Oculis Holding AG's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oculis Holding AG Cash Flow from Others Chart

Oculis Holding AG Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Cash Flow from Others
2.46 4.73 6.56 46.60

Oculis Holding AG Quarterly Data
Dec20 Jun21 Sep21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Others Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.13 3.80 1.35 1.22 2.00

Oculis Holding AG Cash Flow from Others Calculation

Cash Flow from Others for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €8.38 Mil.

Oculis Holding AG Cash Flow from Others Related Terms

Thank you for viewing the detailed overview of Oculis Holding AG's Cash Flow from Others provided by GuruFocus.com. Please click on the following links to see related term pages.


Oculis Holding AG (FRA:CR5) Business Description

Traded in Other Exchanges
Address
Bahnhofstrasse 7, Zug, CHE, 6300
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Oculis Holding AG (FRA:CR5) Headlines

No Headlines